For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

When my spouse and I both faced cancer, maintaining a positive attitude, seeking support, listening empathetically and ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dise ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Paul Critchett battled Veterans Affairs for years, certain his terminal cancer diagnosis stemmed from radiation exposure. On ...

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Cyclacel Pharmaceuticals to ...

Thousands of blood cancer survivors have received life-saving treatment thanks to a small army of inspired cyclists, hikers, ...

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...